about
Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studiesGrey matter lesions in MS: from histology to clinical implications.The puzzle of multiple sclerosis: gray matter finds its place.Cortical lesions and cognitive impairment in multiple sclerosis.Cortical pathology and cognitive impairment in multiple sclerosis.Cortical relapses in multiple sclerosis.Anatomical correlates of cognitive functions in early Parkinson's disease patients.Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension studyThe Parallel Analysis of Phase Sensitive Inversion Recovery (PSIR) and Double Inversion Recovery (DIR) Images Significantly Improves the Detection of Cortical Lesions in Multiple Sclerosis (MS) since Clinical Onset.Natalizumab in the pediatric MS population: results of the Italian registryHeterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion studyIntracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis.Low degree of cortical pathology is associated with benign course of multiple sclerosis.Increased incidence of multiple sclerosis in the Veneto region, Italy.Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.Cortical lesion load associates with progression of disability in multiple sclerosis.Cortical diffusion-tensor imaging abnormalities in multiple sclerosis: a 3-year longitudinal study.Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study.No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset.Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis.A case of relapsing-remitting tumour-like inflammation of the central nervous system.MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis.Fluctuations of MS births and UV-light exposure.Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantroneNatalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological SocietyInverse correlation of genetic risk score with age at onset in bout-onset and progressive-onset multiple sclerosisSevere relapses under fingolimod treatment prescribed after natalizumabUrinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk StratificationEffect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosisThe predictive value of gray matter atrophy in clinically isolated syndromesCerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset
P50
Q28743636-F5A4895A-FB30-4E13-8455-EF143925BE4FQ30574566-976D17B4-53E9-4410-93C0-E9B14646ECD3Q33352371-495537B9-698B-4BAC-A344-7213DCC064FFQ33634154-7F2F99CA-D26C-4CD8-A842-51696DDCCD72Q33837296-70EC4505-04BD-4C25-8632-96D7B5B8F563Q34467914-01E6980B-8142-411A-A98D-A899C3BF08A4Q34745456-8AD25E40-03BE-4929-8646-F4573DEB76E2Q35159288-6AAD48B8-BB61-44BC-9E9D-6976AB4ABEE5Q35641249-DBE8B480-8D99-45A9-90A0-3D59CE105983Q35788938-EE98D68A-0FC6-4E33-8A5E-F3B3D5C7B2FAQ36655414-E72D04F0-954F-4215-9E5B-691C42D04324Q39811998-B703CFFF-749C-41B6-A6FC-0258F04B2D86Q44584762-B9EF9C51-6BEF-4E28-83AD-B89BED903439Q44707920-C2D1F731-F929-4750-9F77-B6C7480EC215Q46289478-941EF685-C029-48F9-A571-FF5F0E868D5EQ46433545-57EE6327-4F18-4245-BF23-1B23A1966D64Q48336159-BA0BBF2F-CF20-49F8-9C03-9EEE9EA4776AQ48819367-B50298AF-D0C3-4A1F-A771-639A944E4624Q48918436-EED27983-AE1E-455F-A343-1962849DABDBQ51510687-BB4DE6FB-132D-4CCB-898B-BC42A4FA63A2Q51666856-F12AD577-1F3D-45B6-AEED-39EE5E73EF4EQ52149420-3AFC7A2D-FC96-4EC8-B7F0-48A8F71BC2BEQ52152218-F9307273-CE62-43B5-A503-3D4C368C93F4Q53123917-D0292540-8868-4F24-83E8-51459B245733Q59389213-CC7007EB-D365-4628-8FB2-953DE39F11F8Q59389216-DC8F9FC1-C411-451B-A5A2-1609E4AA51C6Q59683405-8C8199E3-7A37-4E4F-8DAE-51B75FB6C965Q61231049-BE305FE1-45A8-4FD4-B757-9961DD41063DQ61657742-C2BC7425-6CC5-45E4-BDF7-34FA20B5CCFFQ83178639-1378DF00-A15D-4CCB-84F1-180697D6A1F8Q84197250-1113DDD4-DE8B-46E2-BB8B-151400618BBBQ87493735-728BBECA-BB6B-4EE8-A249-94432125BFF3
P50
description
investigador
@es
researcher
@en
name
Paolo Gallo
@en
type
label
Paolo Gallo
@en
prefLabel
Paolo Gallo
@en
P31
P496
0000-0003-3886-4181